Zantac Heartburn Medication
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
Class-Action Tracker
The Latest
TINA.org Tells DOT: Don’t Muddy Airline Pricing
A proposed rule change could make it harder to know what you’ll actually pay for a flight.
Greenpeace International: SLAPP Suit
Corporate bullies are weaponizing the legal system to silence the truth.
Tinggly
TINA.org unwraps the hidden cost of these gift boxes.
Alani Nu Facing Increased Scrutiny over Marketing to Kids
Following lawsuit, Texas AG launches probe into energy drink’s “youth-oriented branding strategies.”
Harper & Wells Boston
What you need to know about this shady e-commerce site.